Eric Umbreit

The SUO is pleased to introduce FUO: Future Urologic Oncologists, an immersive, in-person educational program designed to introduce senior urology residents to the clinical, collaborative, and leadership dimensions of Urologic Oncology. Learn more here: bit.ly/4bGE0UI

Innovation isn’t about adding features. It’s about solving real problems in the OR. Reach Assist on the da Vinci SP shows what happens when R&D listens to surgeons who actually use the system. This is progress. 👏🏼 @IntuitiveSurg #roboticsurgery

21 months in the making. Stacked every opportunity to get here.

Seahawks back to the Superbowl!!! Let's go revenge those Pats!!! Let's Go!

@urorogerio @MickeyBmickeyB @asajimd Game changer for some cases. Love that I don't have to change instrument location.

Huge fan of new reach assist on SP! Makes burping in and out a lot smoother and safer. Reach assist enabled when CRC is activated and allows you to advance or retract 3 cm at a time while holding your instruments still @MickeyBmickeyB @asajimd

This is a painful article to read. Its essential that clinical trialists only bring on studies to their centers that they believe have the potential to help their patients beyond the status quo. bloomberg.com/features/2025-…

Thirty Years of Ortho: What I’d Tell the Next Generation I’ve been an orthopedic surgeon for three decades. Long enough to see techniques come and go, implants rise and fall, and the pendulum of “standard practice” swing back and forth more times than I can count. What hasn’t changed are the pressures that come with the job… and the quiet lessons you don’t fully understand until you’ve liv,ed them. If I were talking to the next generation—residents, fellows, the young attendings just getting their legs under them… this is what I’d tell them. You can’t build a meaningful career on RVUs. You can meet every target and still feel empty. A career that lasts is built on trust, judgment, and relationships. You don’t measure that in productivity metrics. A good surgeon listens more than they talk. People think surgery is a technical field, but the real work is in understanding what someone is actually asking of you. Most patients are just scared. They don’t need your scalpel, no matter what the MRI shows. Half the mistakes in this profession start with bad listening. Master the anatomy. Master the craft. But learn the limits too. Early in your career, you’re focused on what you can do. With experience, you start to appreciate what you shouldn’t do. Judgment is a superpower. Protect your time, or the system will take every minute you allow it to. Learn to say no!!! There’s no shortage of demands. Notes. Inboxes. Meetings. Every one of them feels urgent. Some of you might actually feel important when you go to meetings... But... None of them is worth sacrificing your sanity or the people waiting for you at home. Seek colleagues, not titles. Promotions and committee seats feel important for a season, but it’s just fluff, and nothing gets accomplished in those meetings anyway. Your strength matters more than you realize. Not your technical strength—your physical and emotional strength. You can’t take care of people if your own health fades. Move, lift, sleep, and protect your energy. A worn-out surgeon becomes brittle. Be the doctor you’d want for your family. You need a life outside the operating room if you want a long life inside it. The surgeons who last aren’t the ones who work the most—they’re the ones who stay grounded. They have people they care about, interests that pull them away from medicine, and enough perspective to know that identity and work are not the same thing. Thirty years in, the operations are only part of the story. What keeps you going is the purpose behind the work—helping people move, reassuring them when they’re scared, giving them back pieces of their life. That’s the part that never gets old.

"WR1" 1️⃣ REPOST = 1️⃣ VOTE #ProBowlVote + @jaxon_smith1

Reminder for all @UroOnc Program Directors and APDs. SUO is hosting a fellowship retreat prior to this years winter meeting to discuss best practice for Research, MultiD, Clinical, Career Dev. Wednesday, Dec 3rd 7-11am. All programs should have representation present!

@tompowles1 @montypal But NIAGARA doesn't show this. -Ve patients also benefited. Atezo may just be a bad drug compared to others. Await MODERN, but decision will still be based on regimen first, ctDNA status second.

3/5 IMVIGOR011 #ESMO25 Atezo vs placebo in ctDNA+ve UC post cystectomy hit OS/PFS.It also tracks outcomes in the ctDNA-ve supporting a ctDNA adjusted approach, potentially sparing persistently negative patients adjuvant therapy. What is its relevance in the era of perioparive IO?

Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?

SP robotic approach has really taken off in my practice. Almost all radical prostate and most kidney surgeries. Nephrouretectomy yesterday was super slick, easy to get to bladder and do retroperitoneal nodes. This platform will continue to grow.

Focal therapy program for prostate cancer off the ground and running at UT Health San Antonio! Great work @drfurkandursun! @UTHealthSA @UTHSAUro

In memoriam: Dr. Donald G. Skinner keck.usc.edu/news/in-memori…

@AnisToumeh @tompowles1 That's the question: ctDNA + and - improved in NIAGRA. So, does the drug matter too? Probably.

@tompowles1 Good news and look forward to seeing the data. Wonder how this would apply in the context of NIAGRA, especially the adjuvant portion.

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. natera.com/company/news/i…

But are other IO better, i.e. durvalumab. Azteo may work here, but NIAGRA showed improvement in ctDNA + and -

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last natera.com/company/news/i…

@tompowles1 But are other IO better, i.e. durvalumab. Azteo may work here, but NIAGRA showed improvement in ctDNA + and - , which you obviously know :)

@LauraBukavinaMD Very cool. I will do this during my next robotic ILND.

@umbreite For penile? Actually into the skin where the tumor used to be on the same side , 2 mg usually . They are positive most of the time

@AdityaBagrodia @UCSDCancer @UCSD_Urology @DrDarrenFeldman @DrRanaMcKay @uroegg @siadaneshmand @RichMatulewicz @nirmishsingla @drphil_urology @RHamiltonUrol @ClintCaryMD @TestesCancer @drmatthewmurray Big lift. Great job.

Took a village and long time to get here! So excited for CLIA certified miR-371-3p testing @UCSDCancer @UCSD_Urology @DrDarrenFeldman @DrRanaMcKay @uroegg @siadaneshmand @RichMatulewicz @nirmishsingla @drphil_urology @RHamiltonUrol @ClintCaryMD @TestesCancer @drmatthewmurray